Merck & Co. has won US approval for a preventative drug to protect against Respiratory Syncytial Virus (RSV), the most common cause of hospitalization among infants. The Food and Drug Administration approved the shot for children under 1 year old, citing significant clinical trial results. In trials, Merck’s vaccine reduced RSV infection rates by 60% over five months and significantly lowered hospitalizations by 84%. This breakthrough offers new hope to parents seeking protection against a common yet serious infant illness.
Source: https://www.bloomberg.com/news/articles/2025-06-09/merck-says-it-wins-us-approval-for-shot-to-prevent-infant-rsv